Repositori URV

Identificador: imarina:2621837

Handle: https://hdl.handle.net/20.500.11797/imarina2621837

Autores:
Aparicio, J.Terrasa, J.Duran, I.Germa-Lluch, J. R.Girones, R.Gonzalez-Billalabeitia, E.Guma, J.Maroto, P.Pinto, A.Garcia-del-Muro, X.

Resumen:
Testicular cancer represents the most common malignancy in males aged 15-34 years and is considered a model of curable neoplasm. Maintaining success, reducing treatment burden, and focusing on survivorship are then key objectives. Inguinal orchiectomy is the first recommended maneuver that has both diagnostic and therapeutic aims. Most patients are diagnosed with stage I disease (confined to the testicle). Close surveillance and selective, short-course adjuvant chemotherapy are accepted alternatives for these cases. In patients with more advanced disease (stages II and III), 3-4 courses of cisplatin-based chemotherapy (according to IGCCCG risk classification) followed by the judicious surgical removal of residual masses represent the cornerstone of therapy. Poor-risk patients and those failing a first-line therapy should be referred to specialized tertiary centers. Paclitaxel-based conventional chemotherapy and high-dose chemotherapy plus autologous hematopoietic support can cure a proportion of patients with relapsing or refractory disease.